Last updated: February 21, 2026
What is NDC 33342-0260?
NDC 33342-0260 is the code assigned by the FDA to Belantamab Mafodotin-blmf, a monoclonal antibody used to treat relapsed/refractory multiple myeloma. It is marketed under the brand name Blenrep by GlaxoSmithKline. Approved in August 2020, Blenrep targets BCMA (B-cell maturation antigen) and indirectly induces cell death.
Market Position and Competitive Landscape
Indication and Patient Population
- Indication: Multiple myeloma, relapsed or refractory after ≥ 4 prior therapies.
- Estimated Patient Pool: Roughly 30,000–40,000 patients globally, with 15,000–20,000 in the U.S. (based on National Cancer Institute data).
Competitive Drugs
- Carfilzomib (Kyprolis)
- Pomalidomide (Pomalyst)
- Selinexor (Xpovio)
- Idecabtagene Vicleucel (Abecma) — CAR-T therapy approved in 2021
Blenrep faces competition from these agents, often used sequentially or in combination.
Market Dynamics
- The multiple myeloma market is projected to grow at a CAGR of 8% through 2028, driven by rising prevalence and new therapies.
- Blenrep’s niche in heavily pre-treated patients limits its market share, but its unique mechanism sustains demand.
Revenue and Sales Data
Historical Sales
- 2021: $300 million globally (est.)
- 2022: $420 million (est.), reflecting increased adoption
Sales Growth Drivers
- Expanded indications in combination trials.
- Increased prescribing in third-line settings.
- Supportive reimbursement policies for complex treatments.
Price Analysis
- List price (U.S.): Approximately $7,300 per dose.
- Average treatment course: 3.4 doses per patient, costing roughly $24,820.
- Estimated annual treatment cost per patient: $75,000–$80,000, considering administration and supportive care.
Pricing Trends
- Minimal reductions due to the drug’s orphan status and limited price sensitivity in this niche.
- Payer negotiations and specialty pharmacy arrangements influence actual transaction prices, often reducing list prices by 10-15%.
Price Forecasts (Next 5 Years)
| Year |
Predicted Average Wholesale Price (AWP) per Dose |
Notes |
| 2023 |
$7,200 |
Slight reduction from list price, reflecting negotiated discounts |
| 2024 |
$7,000 |
Potential recession in list price due to increased competition |
| 2025 |
$6,800 |
Generic-like price stabilization in niche market |
| 2026 |
$6,500 |
Greater payer pressure, increased biosimilar activity (if applicable) |
| 2027 |
$6,300 |
Market saturation limits price growth |
Regulatory and Policy Impact
- Reimbursement: Medicare Parts B and D coverage, with prior authorization establishing access.
- Pricing regulations: Price increases are constrained by federal and state policies.
- Potential biosimilar entry: No biosimilars available yet, but expected within 7–10 years, exerting downward pressure.
Risks to Price and Market Share
- New drug approvals: New therapies offering better efficacy or safety could replace Blenrep.
- Market saturation: Limited new patient growth constrains revenue expansion.
- Pricing pressure: Policy shifts toward value-based pricing limit potential increases.
- Biosimilar competition: Entry could reduce prices by 20–30% over a 3–5 year period after launch.
Key Takeaways
- NDC 33342-0260 (Blenrep) is a niche agent, with steady but limited growth driven by its role in late-line multiple myeloma treatment.
- US list prices hover around $7,200–$7,300 per dose, with actual transaction prices slightly lower.
- Sales are projected to increase modestly through 2027, with prices gradually declining due to industry and policy forces.
- Market entrants and biosimilar competition pose long-term risks to pricing and market share.
FAQs
1. What are the main drivers of Blenrep’s market demand?
Primarily, treatment of relapsed/refractory multiple myeloma patients who have exhausted other options. The orphan status and limited alternatives sustain demand.
2. How competitive is Blenrep in its market?
It faces competition from CAR-T therapies and other targeted agents, but its unique mechanism and approval for heavily pre-treated patients sustain its niche.
3. What factors could reduce Blenrep’s future pricing?
Introduction of biosimilars, new therapies providing superior efficacy, payer negotiations, and policy shifts toward price regulation.
4. How does current pricing compare internationally?
Prices vary; European markets generally see 10-15% discounts compared to US list prices, influenced by healthcare systems and negotiation powers.
5. Are there upcoming regulatory changes that could influence prices?
Potential changes in drug pricing policies, especially in the US and Europe, could lead to stricter controls on list price increases and promote biosimilar uptake.
References
- U.S. Food and Drug Administration. (2020). Blenrep (belantamab mafodotin-blmf) approval letter.
- IQVIA. (2022). Market Intelligence Reports on Multiple Myeloma Therapies.
- National Cancer Institute. (2022). Multiple Myeloma Overview and Patient Statistics.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for complex biologics.
- Evaluate Pharma. (2022). Oncology drug market forecasts and biosimilar entry analyses.
